Carlos H Barrios
Overview
Explore the profile of Carlos H Barrios including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
86
Citations
12602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Schettini F, Chic N, Braso-Maristany F, Pare L, Pascual T, Conte B, et al.
NPJ Breast Cancer
. 2023 Apr;
9(1):32.
PMID: 37120452
No abstract available.
12.
Sternberg C, Davis I, Mardiak J, Szczylik C, Lee E, Wagstaff J, et al.
J Clin Oncol
. 2023 Apr;
41(11):1957-1964.
PMID: 37018920
Purpose: Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-Kit. This randomized, double-blind, placebo-controlled phase III study evaluated efficacy and safety...
13.
Holmes F, Moy B, Delaloge S, Chia S, Ejlertsen B, Mansi J, et al.
Eur J Cancer
. 2023 Mar;
184:48-59.
PMID: 36898233
Background: ExteNET showed that neratinib, an irreversible pan-HER tyrosine kinase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved invasive disease-free survival in women with early-stage HER2-positive breast cancer....
14.
Rugo H, Cortes J, Barrios C, Cabrera P, Xu B, Huang C, et al.
Future Oncol
. 2022 Oct;
PMID: 36268941
Triple-negative breast cancer (TNBC) has the highest rate of distant metastasis and poorest overall survival among breast cancer subtypes. In a phase II study, adagloxad simolenin (AdaSim), a synthetic Globo...
15.
Barrios C, Saji S, Harbeck N, Zhang H, Jung K, Patel S, et al.
NPJ Breast Cancer
. 2022 Sep;
8(1):108.
PMID: 36123366
Patient-reported outcomes data assessing patients' experience of immunotherapy treatment burden in potentially curable early-stage triple-negative breast cancer (TNBC) are lacking. These patient-reported data inform clinical benefit and decision-making for adding...
16.
Peters S, Dziadziuszko R, Morabito A, Felip E, Gadgeel S, Cheema P, et al.
Nat Med
. 2022 Aug;
28(9):1831-1839.
PMID: 35995953
Tumor mutational burden (TMB) is being explored as a predictive biomarker for cancer immunotherapy outcomes in non-small cell lung cancer. BFAST (NCT03178552)-an open-label, global, multicohort trial-evaluated the safety and efficacy...
17.
Cortes J, Rugo H, Cescon D, Im S, Yusof M, Gallardo C, et al.
N Engl J Med
. 2022 Jul;
387(3):217-226.
PMID: 35857659
Background: In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced triple-negative breast...
18.
Reinert T, Goncalves A, de Resende C, Barrios C
Eur J Cancer
. 2022 Jul;
173:30-32.
PMID: 35841844
No abstract available.
19.
Huober J, Barrios C, Niikura N, Jarzab M, Chang Y, Huggins-Puhalla S, et al.
J Clin Oncol
. 2022 Jun;
40(25):2946-2956.
PMID: 35763704
Purpose: Combining standard of care (pertuzumab-trastuzumab [PH], chemotherapy) with cancer immunotherapy may potentiate antitumor immunity, cytotoxic activity, and patient outcomes in high-risk, human epidermal growth factor receptor 2 (HER2)-positive early...
20.
van Mackelenbergh M, Seither F, Mobus V, OShaughnessy J, Martin M, Joensuu H, et al.
Eur J Cancer
. 2022 Mar;
166:185-201.
PMID: 35305453
Background: Despite the large number of patients with early breast cancer (EBC) who have been treated with capecitabine in randomised trials, no individual patient data meta-analysis has been conducted. The...